Skip to content

BioArctic employs Gunilla Andersson as Senior Director HR

Non Regulatory

Stockholm, Sweden, December 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Gunilla Andersson assumes the new position as Senior Director HR in the management team as of January 1, 2019. The position encompasses a strategic focus on leadership and employee development. Gunilla Andersson will be responsible for the Human Resources with focus on securing the right competences and leadership development to further enhance BioArctic’s attractiveness as an employer and position as a world-leading biopharmaceutical company in neurodegenerative diseases.

“This is a strategically important recruitment and we welcome Gunilla’s many years of experience in competence and leadership development including value-based cultures in knowledge-intensive companies. In addition, we have collaborated with Gunilla as HR consultant since 2014 and she has therefore already valuable insights in BioArctic’s business and organization. It is a pleasure to welcome Gunilla to the management team,” says Gunilla Osswald, BioArctic’s CEO.

Gunilla Andersson has nearly 30 years of experience as HR consultant and HR manager from educational organizations and pharmaceutical companies like Pharmacia and Novartis among others. For the past 17 years, she has managed her own consulting company focusing on HR, leadership and recruitment. She has a B.Sc. Human Resource Development and Labour Relations from Lund University, Sweden.

“It is important for us to be an attractive employer. We are proud of that BioArctic recently was honored for sharing the second place of the Allbright Prize 2018,” says Gunilla Osswald.

The foundation Stiftelsen Allbright presents annually a prize to the Swedish listed company that has made the best progress in the area of gender equality during the past year. The jury’s motivation was: “BioArctic is prized primarily for a workplace culture that gives men and women the same career opportunities, according to the employees themselves.”

For more information, please contact
Gunilla Osswald, PhD, CEO, BioArctic AB
Telephone: + 46 8 695 69 30

Christina Astrén, Director IR & Communications, BioArctic AB
Telephone: + 46 70 835 43 36

This information was submitted for publication at 08:00 a.m. CET on December 19, 2018.

About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit us at